Study guide

15.2 Clinical Study Designs & Measures of Effect

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

15.2 Clinical Study Designs & Measures of Effect

Key Takeaways Explain This Topic AI

The hierarchy of clinical evidence ascends from expert opinion and observational designs up to randomized controlled trials (RCTs) and systematic reviews/meta-analyses, balancing observational efficiency against interventional control of confounding.

RCT designs include parallel-group, factorial, and crossover designs (requiring sufficient drug washout of at least 5 half-lives to eliminate carryover effects); crossover designs are contraindicated in acute, curable, or rapidly evolving emergency conditions.

Cohort studies follow exposed and unexposed populations over time to calculate Relative Risk (RR), whereas Case-Control studies sample based on outcome presence to calculate Odds Ratios (OR), representing the optimal observational design for rare clinical diseases and severe adverse drug reactions.

Absolute Risk Reduction (ARR = CER - EER) determines the Number Needed to Treat (NNT = 1 / ARR), which must always be rounded UP to the next integer; Number Needed to Harm (NNH = 1 / ARI) must always be rounded DOWN to the preceding integer.

Diagnostic test accuracy evaluates Sensitivity (SnNOut) and Specificity (SpPIn) as intrinsic properties, while Positive and Negative Predictive Values depend directly on pre-test disease prevalence; Likelihood Ratios (>10 or <0.1) drive substantial shifts in post-test disease probability.

Last updated: October 2026

15.2 Clinical Study Designs & Measures of Effect

Note

Independent study resource provided by ExamFinch. Content is organized around official Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination specifications.

The Hierarchy of Clinical Evidence

Evidence-based emergency medicine ranks clinical research designs based on their inherent ability to control for confounding, eliminate systematic bias, and establish causal relationships between pharmacotherapy and clinical outcomes. HIERARCHY OF CLINICAL EVIDENCE

  • ▲
  • / \
  • / \
  • / \
  • / Meta- \
  • /Analyses \
  • / & System- \
  • /atic Reviews \
  • /───────────────\
  • / Randomized \
  • /Controlled Trials \
  • /─────────────────────\
  • / Cohort Studies \
  • / (Prospective/Retro) \
  • /───────────────────────────\
  • / Case-Control Studies \
  • /───────────────────────────────\
  • / Cross-Sectional Surveys \
  • /───────────────────────────────────\
  • / Case Series & Case Reports \
  • /───────────────────────────────────────\
  • / In Vitro Models, Animal Studies, Opinion\
  • └───────────────────────────────────────────┘

Systematic Reviews & Meta-Analyses : Collate and synthesize all available clinical trials meeting predefined eligibility criteria. Meta-analyses quantitatively pool data from homogeneous RCTs using fixed-effect or random-effects models. Results are displayed via forest plots , and study heterogeneity is quantified using the I 2 I^2 I 2 statistic ( < 25 % <25\% < 25% low, 25 % – 50 % 25\%–50\% 25%–50% moderate, > 50 % >50\% > 50% high heterogeneity).

Randomized Controlled Trials (RCTs) : Interventional design allocating subjects to active or control arms via strict random sequence generation. The gold standard for proving pharmacotherapeutic causality.

Cohort Studies : Observational longitudinal design following exposed and unexposed populations over time to assess incidence of outcomes. Establishes temporal sequence; primary measure is Relative Risk (RR) .

Case-Control Studies : Observational retrospective design identifying patients with an outcome (Cases) and matching them with unaffected subjects (Controls) to evaluate prior drug exposure. Primary measure is Odds Ratio (OR) .

Cross-Sectional Studies : Observational assessment of exposure and disease prevalence at a single discrete point in time. Cannot determine temporality or causality.

Case Series and Case Reports : Descriptive, uncontrolled observational reports of novel drug interactions, toxicities, or off-label rescue therapies. Hypothesis-generating only.

In Vitro Research, Animal Models & Expert Opinion : Biological plausibility foundation; lowest clinical certainty.

  • Randomized Controlled Trial (RCT) Architectures
  • Parallel-Group Design

Patients are randomized to two or more distinct arms (e.g., Investigational Drug vs Standard Active Comparator or Placebo) and remain in their assigned treatment groups concurrently for the entire duration of the study. This is the standard architecture for emergency medicine resuscitation and critical care trials.

Crossover Design

Each patient receives both comparative treatments sequentially, acting as their own matched control:

Sequence : Group 1 receives Drug A → \rightarrow → Washout Period → \rightarrow → Drug B. Group 2 receives Drug B → \rightarrow → Washout Period → \rightarrow → Drug A.

The Washout Period : A mandatory drug-free interval designed to eliminate the carryover effect (residual pharmacologic or clinical effects of the first drug persisting into the second treatment phase). The washout period must span at least 5 elimination half-lives ( 5 × t 1 / 2 5 \times t_{1/2} 5 × t 1/2 ​ ) of the initial drug and its active metabolites.

Emergency Medicine Contraindication : Crossover designs are fundamentally invalid in acute, unstable, or curable conditions (e.g., septic shock, cardiac arrest, acute ischemic stroke, status epilepticus, polytrauma). Crossover trials require a stable, chronic baseline condition (e.g., stable chronic asthma, mild persistent pain).

Factorial Design

A factorial design evaluates two or more distinct interventions simultaneously within a single trial population. In a classic 2 × 2 2 \times 2 2 × 2 factorial trial , patients are randomized into four distinct groups:

  • Treatment A + Treatment B
  • Treatment A + Placebo B
  • Placebo A + Treatment B
  • Placebo A + Placebo B

This design allows investigators to evaluate the independent primary effects of both drugs while assessing potential synergistic or antagonistic pharmacological interactions .

Blinding Methodologies

Open-Label : Both clinicians and patients know the assigned therapy. Prone to severe performance and ascertainment bias.

Single-Blind : Only the patient is unaware of treatment assignment.

Double-Blind : Both patient and treating clinical investigators are blinded. Prevents differential co-interventions.

Triple-Blind : Patient, bedside clinical team, and independent outcome adjudication/statistical analysis committees remain blinded until final database lock.

  • Analysis Populations: Intention-to-Treat vs Per-Protocol CLINICAL TRIAL ANALYSIS POPULATIONS
  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Intention-to-Treat (ITT) Analysis │
  • │ • "Once randomized, always analyzed" in originally assigned group │
  • │ • Analyzes all subjects regardless of adherence, crossover, or withdrawal │
  • │ • Preserves prognostic baseline balance achieved by randomization │
  • │ • Prevents attrition bias; reflects real-world clinical effectiveness │
  • │ • Gold standard for SUPERIORITY trials (conservative estimate) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ Per-Protocol (PP) / On-Treatment Analysis │
  • │ • Analyzes ONLY subjects who completed full protocol without violations │
  • │ • Excludes non-compliant patients, dropouts, and treatment crossovers │
  • │ • Introduces significant selection bias and breaks randomization balance │
  • │ • Reflects ideal biological efficacy under perfect compliance │
  • │ • Required alongside ITT in NON-INFERIORITY trials to prevent false claims │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Observational Study Designs: Cohort vs Case-Control vs Cross-Sectional

When randomized trials are unethical, unfeasible, or logistically impractical, observational study designs provide vital clinical insight:

Study Feature Prospective Cohort Retrospective Cohort Case-Control Cross-Sectional

Starting Point Defined by Exposure status Defined by Exposure status Defined by Outcome / Disease status Population sample at single timepoint

Direction of Inquiry Forward in time (Follow-up) Backward in existing records Backward in time (Exposure history) Simultaneous assessment

Primary Measure Relative Risk (RR) Relative Risk (RR) Odds Ratio (OR) Prevalence Ratio

Optimal Clinical Use Common exposures; establishing incidence & natural history Rapid evaluation of past exposures using electronic health records Rare diseases ( < 5 % <5\% < 5% ) and rare adverse drug reactions Epidemiologic disease surveillance & health resource planning

Key Strengths Establishes temporality; minimizes recall bias; measures multiple outcomes Faster & cheaper than prospective; excellent for ED registries Highly efficient for rare outcomes; small sample size required Rapid, inexpensive; generates clinical hypotheses

Vulnerabilities Expensive; attrition bias; confounding by indication Selection bias; missing historical chart data Severe recall bias ; cannot directly calculate incidence or RR Cannot establish temporality or causality

Emergency Example Following sepsis patients given balanced crystalloids vs saline Chart review of ketamine vs etomidate for post-intubation hypotension Matching ED patients with Stevens-Johnson Syndrome to controls Assessing point prevalence of methicillin-resistant S. aureus

Important

On the BCEMP exam, remember that Case-Control studies cannot measure Relative Risk (RR) because the investigator artificially fixes the proportion of cases and controls (e.g., 1 case to 4 controls). Only the Odds Ratio (OR) can be calculated.

Quantitative Measures of Association & Effect Size

Clinical trials and observational studies summarize binary outcome data using a standard 2 × 2 2 \times 2 2 × 2 contingency table: $2 \times 2$ CONTINGENCY MATRIX

  • Disease / Outcome Present Disease / Outcome Absent Total
  • Exposed / Investigational a b a + b
  • Unexposed / Control c d c + d
  • Total a + c b + d a + b + c + d
  • Experimental Event Rate (EER) : Risk in experimental group = a a + b = \frac{a}{a + b} = a + b a ​
  • Control Event Rate (CER) : Risk in control group = c c + d = \frac{c}{c + d} = c + d c ​
  • Relative Risk (Risk Ratio, RR)

The ratio of the probability of an outcome occurring in the exposed/treated group compared to the unexposed/control group:

RR = EER CER = a / ( a + b ) c / ( c + d ) \text{RR} = \frac{\text{EER}}{\text{CER}} = \frac{a / (a + b)}{c / (c + d)} RR = CER EER ​ = c / ( c + d ) a / ( a + b ) ​

RR = 1.0 \text{RR} = 1.0 RR = 1.0 : No difference in risk between groups.

RR < 1.0 \text{RR} < 1.0 RR < 1.0 : Exposure/treatment reduces risk of outcome (protective effect).

RR > 1.0 \text{RR} > 1.0 RR > 1.0 : Exposure/treatment increases risk of outcome (harmful effect).

Odds Ratio (OR)

The ratio of the odds of exposure among cases compared to the odds of exposure among controls (or odds of event vs non-event):

OR = Odds in Exposed Odds in Unexposed = a / b c / d = a × d b × c \text{OR} = \frac{\text{Odds in Exposed}}{\text{Odds in Unexposed}} = \frac{a / b}{c / d} = \frac{a \times d}{b \times c} OR = Odds in Unexposed Odds in Exposed ​ = c / d a / b ​ = b × c a × d ​

The Rare Disease Assumption : When an outcome is rare in the underlying population (typically incidence < 5 % <5\% < 5% to 10 % 10\% 10% ), a a a is negligible relative to b b b , and c c c is negligible relative to d d d . Under these conditions, a a + b ≈ a b \frac{a}{a+b} \approx \frac{a}{b} a + b a ​ ≈ b a ​ and c c + d ≈ c d \frac{c}{c+d} \approx \frac{c}{d} c + d c ​ ≈ d c ​ , meaning OR ≈ RR \text{OR} \approx \text{RR} OR ≈ RR .

Relative Risk Reduction (RRR)

The proportional reduction in risk achieved by the experimental intervention relative to the baseline control risk:

RRR = CER − EER CER = 1 − RR \text{RRR} = \frac{\text{CER} - \text{EER}}{\text{CER}} = 1 - \text{RR} RRR = CER CER − EER ​ = 1 − RR

Warning

Pharmaceutical literature frequently highlights RRR because it yields large, impressive percentages that can mislead clinicians. For instance, if mortality drops from 2 % 2\% 2% to 1 % 1\% 1% , the RRR is 50 % 50\% 50% , but the true absolute benefit is only 1 % 1\% 1% . Always calculate the Absolute Risk Reduction (ARR).

Absolute Risk Reduction (ARR) & Absolute Risk Increase (ARI)

The true arithmetic difference in event rates between groups:

ARR = CER − EER ( for beneficial interventions ) \text{ARR} = \text{CER} - \text{EER} \quad (\text{for beneficial interventions}) ARR = CER − EER ( for beneficial interventions ) ARI = EER − CER ( for harmful adverse effects ) \text{ARI} = \text{EER} - \text{CER} \quad (\text{for harmful adverse effects}) ARI = EER − CER ( for harmful adverse effects )

Number Needed to Treat (NNT) & Number Needed to Harm (NNH)

NNT = 1 ARR = 1 CER − EER \text{NNT} = \frac{1}{\text{ARR}} = \frac{1}{\text{CER} - \text{EER}} NNT = ARR 1 ​ = CER − EER 1 ​ NNH = 1 ARI = 1 EER − CER \text{NNH} = \frac{1}{\text{ARI}} = \frac{1}{\text{EER} - \text{CER}} NNH = ARI 1 ​ = EER − CER 1 ​

Critical Biostatistical Rounding Rules

NNT Rounding Rule : NNT must always be rounded UP to the next whole integer, regardless of the decimal value. Rounding down would overestimate treatment efficacy. For example, if ARR = 0.043 \text{ARR} = 0.043 ARR = 0.043 ( 4.3 % 4.3\% 4.3% ), NNT = 1 / 0.043 = 23.255 → \text{NNT} = 1 / 0.043 = 23.255 \rightarrow NNT = 1/0.043 = 23.255 → NNT = 24 .

NNH Rounding Rule : NNH must always be rounded DOWN to the preceding whole integer, regardless of the decimal value. Rounding up would underestimate the risk of drug harm. For example, if ARI = 0.038 \text{ARI} = 0.038 ARI = 0.038 ( 3.8 % 3.8\% 3.8% ), NNH = 1 / 0.038 = 26.315 → \text{NNH} = 1 / 0.038 = 26.315 \rightarrow NNH = 1/0.038 = 26.315 → NNH = 26 .

Diagnostic Test Evaluation: 2 × 2 2 \times 2 2 × 2 Matrix & Clinical Utility

Emergency medicine relies heavily on rapid diagnostic tests (point-of-care ultrasound, high-sensitivity troponin, D-dimer, venous blood gas). Test performance is evaluated against a definitive "gold standard" reference: DIAGNOSTIC $2 \times 2$ CONTINGENCY MATRIX

  • Disease Present Disease Absent
  • Positive Index Test True Positive (TP) False Positive (FP)
  • Negative Index Test False Negative (FN) True Negative (TN)
  • Total TP + FN (Total Diseased) FP + TN (Total Non-Diseased)
  • Sensitivity (SnNOut)

The proportion of patients with the disease who test positive:

Sensitivity = TP TP + FN \text{Sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}} Sensitivity = TP + FN TP ​

Clinical Application (SnNOut) : A test with very High Sensitivity , when Negative , rules Out disease. Tests with high sensitivity have very few false negatives. A negative high-sensitivity cardiac troponin or high-sensitivity D-dimer safely excludes acute myocardial infarction or pulmonary embolism in low-to-intermediate risk patients.

Specificity (SpPIn)

The proportion of patients without the disease who test negative:

Specificity = TN TN + FP \text{Specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}} Specificity = TN + FP TN ​

Clinical Application (SpPIn) : A test with very High Specificity , when Positive , rules In disease. Highly specific tests have very few false positives. Non-contrast CT brain demonstrating hyperdense intracranial blood has near- 100 % 100\% 100% specificity, definitively ruling in hemorrhagic stroke.

Predictive Values: The Influence of Disease Prevalence

Positive Predictive Value (PPV) : Probability that a patient with a positive test truly has the disease: PPV = TP TP + FP \text{PPV} = \frac{\text{TP}}{\text{TP} + \text{FP}} PPV = TP + FP TP ​

Negative Predictive Value (NPV) : Probability that a patient with a negative test is truly free of disease: NPV = TN TN + FN \text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}} NPV = TN + FN TN ​

Important

Sensitivity and Specificity are intrinsic operating properties of a diagnostic test that remain relatively constant across patient cohorts. In contrast, PPV and NPV depend directly on disease prevalence (pre-test probability) in the tested population:

As disease prevalence increases : PPV increases , while NPV decreases.

As disease prevalence decreases : NPV increases , while PPV decreases.

Likelihood Ratios (Prevalence-Independent Test Power)

Likelihood ratios quantify the magnitude of shift from pre-test probability to post-test probability, independent of population disease prevalence:

Positive Likelihood Ratio (LR+) = Sensitivity 1 − Specificity = True Positive Rate False Positive Rate \text{Positive Likelihood Ratio (LR+)} = \frac{\text{Sensitivity}}{1 - \text{Specificity}} = \frac{\text{True Positive Rate}}{\text{False Positive Rate}} Positive Likelihood Ratio (LR+) = 1 − Specificity Sensitivity ​ = False Positive Rate True Positive Rate ​ Negative Likelihood Ratio (LR-) = 1 − Sensitivity Specificity = False Negative Rate True Negative Rate \text{Negative Likelihood Ratio (LR-)} = \frac{1 - \text{Sensitivity}}{\text{Specificity}} = \frac{\text{False Negative Rate}}{\text{True Negative Rate}} Negative Likelihood Ratio (LR-) = Specificity 1 − Sensitivity ​ = True Negative Rate False Negative Rate ​

  • Likelihood Ratio Magnitude of Shift in Post-Test Probability Clinical Utility in Emergency Decision-Making
  • LR+ > 10 >10 > 10 Substantial increase ( > 45 % >45\% > 45% ) Often definitive; virtually confirms diagnosis

LR+ 5 5 5 to 10 10 10 Moderate increase ( 30 % – 45 % 30\%–45\% 30%–45% ) Clinically meaningful shift; usually warrants therapy

LR+ 2 2 2 to 5 5 5 Small increase ( 15 % – 30 % 15\%–30\% 15%–30% ) Modest contribution; rarely definitive alone

LR = 1.0 = 1.0 = 1.0 No change ( 0 % 0\% 0% ) Completely uninformative test; post-test prob = pre-test prob

LR- 0.2 0.2 0.2 to 0.5 0.5 0.5 Small decrease ( − 15 % -15\% − 15% to − 30 % -30\% − 30% ) Modest contribution; rarely sufficient to rule out

LR- 0.1 0.1 0.1 to 0.2 0.2 0.2 Moderate decrease ( − 30 % -30\% − 30% to − 45 % -45\% − 45% ) Clinically meaningful reduction in probability

LR- < 0.1 <0.1 < 0.1 Substantial decrease ( > 45 % >45\% > 45% ) Often definitive; safely rules out acute disease